Drug intelligence / Profile preview

CTx011

Development stage: Unknown
Lead developer: Complement Therapeutics
Modality: Gene Therapies
Administration: Intravenous

Overview

CTx011 is a gene therapy developed by Complement Therapeutics. It is designed to treat geographic atrophy (GA), an advanced form of age-related macular degeneration (AMD). The therapy utilizes an AAV (adeno-associated virus) vector to express an anti-C3 mini-body, known as AMY-101, which targets the complement component C3.

Targets

Beyond the preview

Go deeper on CTx011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTx011.

Explore the full profile